Company History
Q Scientific Consulting Limited (QSCL), located in its offices in Harrogate UK, was founded in 2008 from two existing consultancies, each with over 10 years of advisory experience. QSCL’s clients range from start-up virtual companies, members of FTS250, to global professional services organisations. QSCL’s employees have been helping companies develop pharmaceuticals since 1997. QSCL therefore has extensive experience in safety evaluation and regulatory affairs, and with associates, in CMC and clinical trials.
Our consultants
Chris Collins BSc(Hons), C.Biol, ERT is a Director of Q Scientific Consulting Limited and a recognized expert in inhalation safety evaluation. An established consultant with 3 decades international experience with previous scientific and contracting experience at 3 major international CROs. Two decades of experience in drug development as a member of project teams with CMC, device and clinical colleagues and experienced in pharmacokinetics and interfacing to early clinical, research governance and clinical ethics. Product areas include dry powder and metered dose inhalers, generics, mucoactives, bronchodilators and CNS products. Experienced author/reviewer of confidential and scientific reports and clinical trial application and regular attendee at UK, EU and FDA meetings.
Nicholas Shepherd BSc(Hons), Senior Consultant
An established inhalation toxicologist with over 20 years' experience in
the conduct of regulatory toxicity studies to support all clinical phases.
His skills are focused on the design, outsourcing and review of preclinical
studies in particular by the nasal and inhalation routes including biotech
pharmaceuticals. This work includes membership of project teams, contract
development and price review, selection, monitoring and inspection of CROs,
with particular emphasis on practical and technical issues.
Thomas Smith BSc(Hons), Senior Consultant
An experienced general toxicologist and animal facility manager with 20
years’ experience in various CROs in the conduct, reporting and reviewing
of nonclinical safety evaluation including carcinogenicity studies and biotechnology
products. Able to offer strategic advice on nonclinical development planning
and contracting, practical experience of day to day monitoring and problem
solving. Substantial experience in reviewing scientific and expert reports,
and writing nonclinical overviews and CTDs including generic drugs.